Bill Text: TX HB30 | 2019-2020 | 86th Legislature | Introduced
Bill Title: Relating to the transfer of unused long-acting reversible contraceptive products under Medicaid and the Healthy Texas Women program.
Sponsorship: Partisan Bill (Democrat 1)
Status: (Introduced - Dead) 2019-03-06 - Withdrawn from schedule [HB30 Detail]
Download: Texas-2019-HB30-Introduced.html
| 86R1341 KKR-D | ||
| By: Hinojosa | H.B. No. 30 | |
|
|
||
|
|
||
| relating to the transfer of unused long-acting reversible | ||
| contraceptive products under Medicaid and the Healthy Texas Women | ||
| program. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Subchapter B, Chapter 531, Government Code, is | ||
| amended by adding Section 531.0742 to read as follows: | ||
| Sec. 531.0742. TRANSFER OF UNUSED LONG-ACTING REVERSIBLE | ||
| CONTRACEPTIVE PRODUCT. (a) In this section: | ||
| (1) "Healthy Texas Women program" means a program | ||
| operated by the commission that is substantially similar to the | ||
| demonstration project operated under former Section 32.0248, Human | ||
| Resources Code, and that is intended to expand access to preventive | ||
| health and family planning services for women in this state. | ||
| (2) "Long-acting reversible contraceptive product" | ||
| means a method of birth control that provides effective | ||
| contraception for an extended period without requiring user action. | ||
| The term includes an injection, intrauterine device, and subdermal | ||
| contraceptive implant. | ||
| (b) In accordance with commission rules, a health care | ||
| provider under Medicaid or the Healthy Texas Women program may | ||
| transfer to a Medicaid or Healthy Texas Women program recipient a | ||
| long-acting reversible contraceptive product prescribed by the | ||
| provider to another recipient if: | ||
| (1) the long-acting reversible contraceptive product: | ||
| (A) was not delivered to or used by the recipient | ||
| to whom the contraceptive product was initially prescribed; | ||
| (B) is contained in the contraceptive product's | ||
| original packaging and that packaging is unopened; and | ||
| (C) is prescribed to and is medically appropriate | ||
| and not contraindicated for the recipient to whom the contraceptive | ||
| product is being transferred; and | ||
| (2) at the time of the transfer: | ||
| (A) the contraceptive product has been in the | ||
| health care provider's possession for at least 12 weeks following | ||
| the date of the original prescription for the product; or | ||
| (B) the health care provider has written | ||
| confirmation that the recipient to whom the contraceptive product | ||
| was initially prescribed no longer wishes to receive or use the | ||
| product. | ||
| SECTION 2. Not later than March 31, 2020, the executive | ||
| commissioner of the Health and Human Services Commission shall | ||
| adopt rules necessary to implement Section 531.0742, Government | ||
| Code, as added by this Act. | ||
| SECTION 3. If before implementing any provision of this Act | ||
| a state agency determines that a waiver or authorization from a | ||
| federal agency is necessary for implementation of that provision, | ||
| the agency affected by the provision shall request the waiver or | ||
| authorization and may delay implementing that provision until the | ||
| waiver or authorization is granted. | ||
| SECTION 4. This Act takes effect September 1, 2019. | ||
